⬆ The upside of AI ⬆For all the concern surrounding artificial intelligence, it's worth remembering why so many researchers remain optimistic about its potential. In a recent 60 Minutes interview, Google DeepMind CEO and Nobel laureate Demis Hassabis suggested that AI could dramatically accelerate drug discovery—reducing development timelines from years to months or even weeks. He even suggested AI could help us cure—or at least effectively treat—many diseases within the next decade. That optimism isn't limited to DeepMind. Anthropic recently introduced Claude Science, a new AI workbench designed specifically for scientific research. Rather than creating another chatbot, the company built a platform that helps researchers analyze literature, work with biological data, and streamline computational research and drug discovery workflows. It's another sign that the race to build better AI is increasingly becoming a race to accelerate medical breakthroughs. Whether these ambitious predictions ultimately prove accurate remains to be seen. But one thing is becoming increasingly clear: the healthcare industry isn't waiting to find out. AI is already moving from the lab into the scientific process itself, and that's good news for patients everywhere. Read more: ⬇ The downside of AI ⬇As organizations race to deploy AI, many are investing heavily in new capabilities while spending comparatively little on governance and oversight. One recent analysis found that organizations are spending roughly $1 on AI governance and security for every $735 invested in expanding AI capabilities. That's a sobering reminder that building more powerful AI is only part of the challenge. Ensuring those systems are transparent, trustworthy, and appropriately supervised may ultimately prove just as important. If we're serious about keeping humans in the loop, governance can't be an afterthought. Read the full story here.
|
